久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

BIZCHINA> Top Biz News
Profits up for flu vaccine makers
By Ding Qingfen (China Daily)
Updated: 2009-11-16 07:55

Profits up for flu vaccine makers

Primary school students receive injections of anti-H1N1 influenza medicine in Hunan province. GlaxoSmithKline (GSK) has received orders for 1.2 million packs of its anti-H1N1 influenza medicine, Relenza, from the Chinese government. [Asianewsphoto]

International pharmaceutical companies are cashing in on China's efforts to protect its people from the H1N1 pandemic with anti-influenza medicines.

GlaxoSmithKline (GSK), a leading international pharmaceutical company and China's largest by sales volume, received approval from the State Food and Drug Administration for its anti-H1N1 influenza medicine to enter the China market in July.

Since then, GSK has prepared 1.2 million packs of the anti-H1N1 influenza medicine called Relenza available for governments at all levels in China. The governments are storing the anti-virus in anticipation of a massive flu outbreak in coming months.

"GSK expects very strong demand for Relenza this year in China," Mark Reilly, general manager of GSK China, told China Business Weekly.

Profits up for flu vaccine makers

Chen Zhaorong, area medical manager at GSK China, also predicted that GSK will receive more orders in the months ahead.

"Compared with that from the other nations worldwide, China's orders are still small (for GSK)," Chen said.

Actually, the production capacity for Relenza is around 60 million packs. GSK has contracts in place to supply Relenza to over 60 economies. Of which, at least 10 percent of its new production have been allocated for developing nations.

But Chinese rules require that only governments can purchase the anti-H1N1 flu medicine. Relenza is still unavailable for sale to consumers.

As the weather turns colder, China is now bracing for a major H1N1 flu case outbreak. As of Nov 11, more than 62,871 cases were reported in 31 provinces, municipalities and autonomous regions of the Chinese mainland. About 32,000 cases were reported just since Oct 12.

Related readings:
Profits up for flu vaccine makers 8M+ Chinese inoculated with A(H1N1) flu vaccine
Profits up for flu vaccine makers Two died after inoculation of A(H1N1) flu vaccine
Profits up for flu vaccine makers Beijing to extend A(H1N1) flu vaccine inoculation
Profits up for flu vaccine makers H1N1 vaccine and common flu vaccine to merge

"Many regions are entering the traditional period for possible flu outbreaks, which will last for two to three months, and prevention and control work is becoming tougher," said Liang Wannian, vice director of the health emergency office under the Ministry of Health.

The Chinese government plans to allocate 1.09 billion yuan ($159.65 million) for prevention and treatment of the flu, including purchases of vaccinations, anti-viral medicines and medical instruments.

The huge investment is attracting global players like GSK. To meet the growing demand for anti-virals in China, GSK is considering investing in a manufacturing facility to produce Relenza for the country, said the GSK's Reilly, declining to elaborate.


(For more biz stories, please visit Industries)

   Previous page 1 2 Next Page  

主站蜘蛛池模板: 亚洲在线欧美 | 亚洲图片偷拍自拍 | 欧美大片国产在线永久播放 | 三级黄色网址 | 99国产福利视频在线观看 | 天天爽夜夜操 | 亚洲欧美精品一区天堂久久 | 国产成人一区免费观看 | 欧美视频区 | 老色99久久九九精品尤物 | 国产三级在线免费观看 | 成人毛片免费视频播放 | 99爱在线视频这里只有精品 | 成年人免费毛片 | 日本人视频网站一 | 免费在线亚洲视频 | 成人网视频在线观看免费 | 国产精品拍自在线观看 | 成人羞羞视频国产 | 欧美经典成人在观看线视频 | 国产露脸3p普通话 | 日韩在线三级视频 | 欧美成人一区二区三区在线视频 | 日韩精品网 | 久久久久9999 | 欧美视频一区二区专区 | 成人久久影院 | 亚洲毛片免费观看 | 国产精品久久在线观看 | 另类欧美日韩 | 欧美成人影院在线观看三级 | 欧美一级黄 | 国产高清美女一级a毛片久久w | 欧美久久久久久 | 免费国产黄 | 欧美日韩国产亚洲综合不卡 | 一区二区三区四区视频在线观看 | 国内精品国语自产拍在线观看55 | 鲁老汉精品视频在线观看 | 久久高清精品 | 亚洲一区二区中文 |